OPDIVO™ is the first and only immuno-oncology therapy in lung cancer in Canada, which uses the body's own immune system to fight cancer, offering improved survival to more patients MONTREAL, March 1,
Category: Treatment Updates
BLINCYTO is the First-and-Only Bispecific CD19-Directed CD3 T-Cell Engager (BiTE®) Immunotherapy Approved by Health Canada
Mississauga, ON. (January 12, 2016) – Amgen Canada Inc., today announced that Health Canada has granted conditional* approval of BLINCYTO™ (blinatumomab) for the treatment of adults with Philadelphia chromosome-negative (Ph-) relapsed or
Health Canada Approves IMBRUVICA? by Priority Review, Giving Physicians and Patients a Much-Needed Option in the Fight Against Chronic Lymphocytic Leukemia
Ontario patients living with CLL and SLL who are eligible will now have access to IMBRUVICA® under the Exceptional Access Program of the Ontario Drug Benefit Program. Eligibility criteria include those patients
Xofigo is added to the Liste des médicaments ? Établissements in Quebec
TORONTO, ON, July 27, 2015 – Men in Quebec are one step closer to accessing Xofigo (radium Ra 223 dichloride), for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases
Biosimilars Illustrated Videos